Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

Annemarie Meenhuis, Peter A. van Veelen, Hans de Looper, Nicole van Boxtel, Iris J. van den Berge, Su M. Sun, Erdogan Taskesen, Patrick Stern, Arnoud H. de Ru, Arjan J. van Adrichem, Jeroen Demmers, Mojca Jongen-Lavrencic, Bob Löwenberg, Ivo P. Touw, Phillip A. Sharp, Stefan J. Erkeland

Blood (2011) 118 (4): 916–925.

https://doi.org/10.1182/blood-2011-02-336487

Published: 2011

Includes: Supplemental data

Journal Articles

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Tony Muchamuel, Monette Aujay, Mark K Bennett, PhD, Maya Dajee, Susan Demo, PhD, Christopher J Kirk, Ph.D, Ying Fang, Jing Jiang, M.D., Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, PhD, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou, PhD

Blood (2008) 112 (11): 3671.

https://doi.org/10.1182/blood.V112.11.3671.3671

Published: 2008

Journal Articles

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijs W. B. van Leeuwen, Asher A. Chanan-Khan, Robert Z. Orlowski

Blood (2007) 110 (9): 3281–3290.

https://doi.org/10.1182/blood-2007-01-065888

Published: 2007

Includes: Supplemental data

Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3461.

https://doi.org/10.1182/blood.V108.11.3461.3461

Published: 2006

Journal Articles

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Susan D. Demo, PhD, Monette A. Aujay, BS, Eileen Goldstein, BS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Yan Lu, PhD, Kevin D. Shenk, BS, Congcong M. Sun, MS, Catherine Sylvain, PhD, Tina M. Woo, BS, Hanjie Zhou, PhD, Mark K. Bennett, PhD

Blood (2006) 108 (11): 4398.

https://doi.org/10.1182/blood.V108.11.4398.4398

Published: 2006

Journal Articles

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Francesco Parlati, PhD, Monette A. Aujay, B.S., Susan D. Demo, Ph.D., Eileen D. Goldstein, B.S., Jing Jiang, B.S., Christopher J. Kirk, Ph.D., Guy J. Laidig, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Kevin D. Shenk, M.S., Catherine Sylvain, Ph.D., Congcong M. Sun, M.S., Tina M. Woo, B.S., Han-Jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 4392.

https://doi.org/10.1182/blood.V108.11.4392.4392

Published: 2006

Journal Articles

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Christopher J. Kirk, PhD, Monette A. Aujay, B.S., Mark Ho, B.S., Jing Jiang, B.S., Guy J. Laidig, Ph.D., Evan R. Lewis, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Tina M. Woo, B.S., Congcong M. Sun, M.S., Catherine Sylvain, Ph.D., Jinfu Yang, Ph.D., Han-jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 3581.

https://doi.org/10.1182/blood.V108.11.3581.3581

Published: 2006

Journal Articles

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites.

Mark K. Bennett, PhD, Monette A. Aujay, BS, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Guy J. Laidig, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark S. Smyth, PhD

Blood (2005) 106 (11): 2472.

https://doi.org/10.1182/blood.V106.11.2472.2472

Published: 2005

Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD

Blood (2005) 106 (11): 609.

https://doi.org/10.1182/blood.V106.11.609.609

Published: 2005

Journal Articles

SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30 + Malignancies.

Kevin J. Hamblett, Jeremy Barton, Charles G. Cerveny, Jamie B. Andreyka, Kim M. Kissler, Nicole M. Okeley, Ivan Stone, May K. Sutherland, Michael M. Sun, Peter D. Senter, Alan F. Wahl, Nathan C. Ihle

Blood (2005) 106 (11): 610.

https://doi.org/10.1182/blood.V106.11.610.610

Published: 2005

Journal Articles

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, PA, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1576.

https://doi.org/10.1182/blood.V106.11.1576.1576

Published: 2005

Journal Articles

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.

Susan D. Demo, PhD, Tonia J. Buchholz, MS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Carol M. Sullivan, BA, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark K. Bennett, PhD

Blood (2005) 106 (11): 1588.

https://doi.org/10.1182/blood.V106.11.1588.1588

Published: 2005

Journal Articles

CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease

DA Filippa, M Ladanyi, N Wollner, DJ Straus, JP O'Brien, C Portlock, M Gangi, M Sun

Blood (1996) 87 (7): 2905–2917.

https://doi.org/10.1182/blood.V87.7.2905.bloodjournal8772905

Published: 1996

NARROW

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites.

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30 + Malignancies.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.

CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only